Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07410117 · ClinicalTrials.gov registry record · Phase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
A Phase 3 study of Cancer-Associated Thrombosis (CAT), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 860
- Enrollment target
- 5
- Study locations
NCT07410117: Recruiting Phase 3 study of Cancer-Associated Thrombosis (CAT), sponsored by Regeneron Pharmaceuticals.
NCT07410117 is a Phase 3 study of Cancer-Associated Thrombosis (CAT) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 860 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07410117, a Phase 3 study of Cancer-Associated Thrombosis (CAT), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 860 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG REGN7508
Study Locations (5)
Other
- Llc Todua Clinic - Tbilisi
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic - Tbilisi
Florida
- Bioresearch Partner- Hialeah Hospital - Hialeah
Texas
- El Paso Medical Research Institute (Medresearch Inc) - El Paso
Adjara
- LTD High Technology Hospital Medcenter - Batumi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 860 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2030-05-06 |
| Phase | Phase 3 |
What NCT07410117 shows while recruiting
NCT07410117 is an interventional study that assigns participants to a tested intervention. The registered 860 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Cancer-Associated Thrombosis (CAT) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07410117 lists 5 locations in 4 states (Other, Florida, Texas).
Frequently Asked Questions
What is clinical trial NCT07410117 about?
NCT07410117 is a clinical study titled "REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis". This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tum...
What is the current status of trial NCT07410117?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 860 participants. The study started on 2026-03-09. Estimated completion is 2030-05-06.
What conditions does trial NCT07410117 study?
This clinical trial studies the following conditions: Cancer-Associated Thrombosis (CAT).
What interventions are being tested in trial NCT07410117?
The interventions under investigation include: Placebo (DRUG), REGN7508 (DRUG).
Who is sponsoring clinical trial NCT07410117?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07410117 being conducted?
This trial has 5 study locations across Florida, Texas, Adjara. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07410117's enrollment target sits among peer trials
860 380th of 2000 higher than 1,619 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI